Memo: Centers for Medicare & Medicaid Services says health insurers cannot use AI to determine care or deny coverage to members on Medicare Advantage plans
Beth Mole / Ars Technica :
Context & Ripple Effects
CMS had previously supported reimbursement for AI used in clinical diagnosis, including AI tools for diabetic eye disease and stroke detection. This memo draws a consequential boundary between AI that assists clinical care and AI used by insurers to make coverage decisions for Medicare Advantage members.
The boundary also addresses concerns raised in coverage of predictive systems used to time treatment cutoffs for older patients. It matters because Medicare Advantage coverage decisions sit at the point where automated risk assessment can directly affect access to care.
First-order effects
- Medicare Advantage insurers must keep AI from serving as the determinant of care or coverage denials, constraining automated utilization-management and denial workflows for affected members.
- AI vendors and insurer teams supporting these workflows face an immediate need to separate decision support from coverage determination and document the role of people in the process.
Second-order effects
- Insurers may need to redesign prior-authorization and appeals operations around reviewable decision paths, increasing the value of tools that support staff rather than independently resolve cases.
- Model suppliers will be pressed to offer stronger auditability and workflow controls; the distinction is especially relevant as later coverage examines AI in prior-authorization and Medicare claims decisions.
Third-order effects
- The memo points toward a regulated split between AI used to augment diagnosis or administration and AI used to allocate benefits, with the latter receiving more direct oversight.
- If this approach persists, health-insurance AI competition will shift from pure automation toward systems that can demonstrate accountable human oversight and defensible decision records.
The trend: Healthcare AI governance is increasingly focused on limiting automated systems' authority where they can directly determine patients' access to covered care.